- Therapeutics Solution (OTCPK:TSOI +5.6%) has reported a publication from the University of Miami, demonstrating intravenous administration of JadiCells (in-licenced by the company) results in a significant survival improvement in COVID-19 patients.
- The Phase 1/2 trial treated 12 COVID-19 patients with 100M JadiCells at days 0 and 3, and 12 patients received placebo.
- At 28 days 91% of JadiCell treated patients survived, compared to 42% of patients in the placebo group survived.
- On the safety front, no adverse effects associated with JadiCell administration was observed
- In July 2019, Therapeutics Solution obtained an exclusive license for the use of JadiCells in treatment of chronic traumatic encephalopathy and brain injury. JadiCells are a type of "supercharged" mesenchymal stem cells which according to the company, possess superior therapeutic activity as compared to other stem cells.
https://seekingalpha.com/news/3627342-therapeutic-solutions-licensed-stem-cell-show-survival-benefit-in-covidminus-19
Wednesday, October 28, 2020
Therapeutic Solutions' licensed stem cell show survival benefit in COVID-19
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.